Ginkgo Results Presentation Deck

Biosecurity Highlights (Unaudited) $22 Q1 2021 -10% Q1 2021 Biosecurity Revenue ($M) $22 Q2 2021 22% $43 Biosecurity Gross Margin Q2 2021 Q3 2021 48% Q3 2021 $114 Q4 2021 42% Q4 2021 Concentric's pathogen monitoring network has conducted testing across most of the U.S.(1) Demonstrated ability to deliver testing in diverse jurisdictions States in which Concentric has delivered testing services Airport testing locations 7,200,000+ Samples to date 4,000+ Organizations supported to date 4 Key US airports (1) Map shading reflects all states in which Concentric has delivered testing since launching in 2020, not all states currently have active testing. programs. Breadth is important given diverse set of state operating models. Data updated 03/27/22 Expanding our reach through partnerships with Eurofins' Clinical Enterprise and acquisition of Project Beacon COVID-19 Air travel SARS-CoV-2 genomic surveillance program in partnership with XpresCheck and CDC yielded first U.S. detections of Omicron sublineages BA.2 and BA.3 Property of Ginkgo Bioworks - 9 2021 UPDATE & BUSINESS REVIEW

View entire presentation